MBX Biosciences Statistics
Total Valuation
MBX Biosciences has a market cap or net worth of $2.95 billion. The enterprise value is $2.51 billion.
| Market Cap | 2.95B |
| Enterprise Value | 2.51B |
Important Dates
The next estimated earnings date is Friday, August 7, 2026, before market open.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MBX Biosciences has 47.60 million shares outstanding. The number of shares has increased by 112.87% in one year.
| Current Share Class | 47.60M |
| Shares Outstanding | 47.60M |
| Shares Change (YoY) | +112.87% |
| Shares Change (QoQ) | +3.81% |
| Owned by Insiders (%) | 2.92% |
| Owned by Institutions (%) | 84.48% |
| Float | 27.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.74 |
| P/TBV Ratio | 6.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.79, with a Debt / Equity ratio of 0.00.
| Current Ratio | 30.79 |
| Quick Ratio | 30.42 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.73% and return on invested capital (ROIC) is -18.33%.
| Return on Equity (ROE) | -25.73% |
| Return on Assets (ROA) | -17.68% |
| Return on Invested Capital (ROIC) | -18.33% |
| Return on Capital Employed (ROCE) | -22.55% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.37M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +353.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +353.22% |
| 50-Day Moving Average | 44.86 |
| 200-Day Moving Average | 33.75 |
| Relative Strength Index (RSI) | 61.53 |
| Average Volume (20 Days) | 964,741 |
Short Selling Information
The latest short interest is 5.78 million, so 12.14% of the outstanding shares have been sold short.
| Short Interest | 5.78M |
| Short Previous Month | 5.90M |
| Short % of Shares Out | 12.14% |
| Short % of Float | 21.35% |
| Short Ratio (days to cover) | 5.52 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -98.79M |
| Pretax Income | -86.61M |
| Net Income | -86.61M |
| EBITDA | -98.56M |
| EBIT | -98.79M |
| Earnings Per Share (EPS) | -$2.18 |
Balance Sheet
The company has $439.98 million in cash and $555,000 in debt, with a net cash position of $439.42 million or $9.23 per share.
| Cash & Cash Equivalents | 439.98M |
| Total Debt | 555,000 |
| Net Cash | 439.42M |
| Net Cash Per Share | $9.23 |
| Equity (Book Value) | 437.76M |
| Book Value Per Share | 9.20 |
| Working Capital | 433.97M |
Cash Flow
In the last 12 months, operating cash flow was -$77.48 million and capital expenditures -$2.34 million, giving a free cash flow of -$79.82 million.
| Operating Cash Flow | -77.48M |
| Capital Expenditures | -2.34M |
| Depreciation & Amortization | 235,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -79.82M |
| FCF Per Share | -$1.68 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MBX Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -112.87% |
| Shareholder Yield | -112.87% |
| Earnings Yield | -2.93% |
| FCF Yield | -2.70% |
Analyst Forecast
The average price target for MBX Biosciences is $69.00, which is 11.29% higher than the current price. The consensus rating is "Buy".
| Price Target | $69.00 |
| Price Target Difference | 11.29% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |